Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2001-08-27
2002-11-12
Krass, Frederick (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S321000
Reexamination Certificate
active
06479525
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to a novel compound, to processes for preparing it and to its use in treating medical disorders. In particular the present invention relates to a novel derivative of Amlodipine.
2. Description of the Related Arts
Calcium channel blockers (calcium antagonists) are useful in treating cardiac conditions including angina and/or hypertension. Dicarboxylate-dihydropyridine derivatives are generally known to possess calcium channel blocking activity. For example, EP 089 167 and corresponding U.S. Pat. No. 4,572,909 disclose a class of 2-amino group-3,5-dicarboxylate dihydropyridine derivatives as being useful calcium channel blockers. These patents identify that one of the most preferred compounds is 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine. This compound, which is now commonly known as amlodipine, has the following formula:
Amlodipine exhibits good bioavailability and has a long half-life in the body. While a variety of acid addition salts are taught in these patents to be suitable, the maleate salt is identified as the most preferred acid addition salt. However, the commercial product of amlodipine (NORVASC by Pfizer) uses amlodipine besylate (benzene sulfonate) and not amlodipine maleate. Indeed, subsequent patents EP 244 944 and corresponding U.S. Pat. No. 4,879,303 indicate that the besylate salt provides certain advantages over the known salts including good formulating properties. Apparently, amlodipine maleate suffered from tabletting and stability problems so as to cause a switch during development to the besylate salt. (See “Review of Original NDA” for NDA# 19-787 of 10.10.1990, obtainable from FDA under Freedom of Information Act). The stability and tabletting issues/causes are not publicly disclosed in the information available from the FDA.
SUMMARY OF THE INVENTION
The present invention relates to the discovery of a novel derivative of amlodipine, the use thereof, and methods of making the same. Specifically, the present invention provides a compound of the following formula (1):
or a pharmaceutically acceptable salt thereof.
The compound of formula (1) is useful as a calcium channel blocker and thus further aspects of the invention relate to a pharmaceutical composition comprising an effective amount of a compound of formula (1) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient as well as to a method of treating angina or hypertension by administering to a patient in need thereof an effective amount of a compound of formula (1) or a pharmaceutically acceptable salt thereof. Further, the present invention can be used in combination with amlodipine as a pharmaceutically active ingredient composition.
REFERENCES:
patent: 4572909 (1986-02-01), Campbell et al.
patent: 4879303 (1989-11-01), Davison et al.
patent: 4983740 (1991-01-01), Peglion et al.
patent: 5155120 (1992-10-01), Lazar et al.
patent: 5389654 (1995-02-01), Furlan et al.
patent: 5438145 (1995-08-01), Furlan et al.
patent: 6046337 (2000-04-01), Bozsing et al.
patent: 0 089 167 (1986-10-01), None
patent: 0 244 944 (1990-01-01), None
patent: 0 290 211 (1991-09-01), None
patent: 0 534 520 (1997-03-01), None
patent: 0 902 016 (1999-03-01), None
patent: 0 963 980 (1999-12-01), None
patent: 99/25688 (1999-05-01), None
patent: 99/52873 (1999-10-01), None
patent: 00/24714 (2000-05-01), None
patent: 00/35873 (2000-06-01), None
patent: 00/35910 (2000-06-01), None
Alker et al., “Long-acting dihydropyridine calcium antagonists. 9. Structure activity relationships around amlodipine”, Eur J Med Chem (1991) 26, 907-913.
Amlodipine Besylate Monograph, Pharmaeuropa vol. 10, No. 2, 197-198, Jun. 1998.
Faulkner et al., “Absorption of Amlodipine Unaffected by Food”, Arzneim Forsch/Drug Res. 39 (11), No. 7, (1989).
McDaid and Deasy, “Formulation development of a transdermal drug delivery system for amlodipine base”, International Journal of Pharmaceutics 133 (1996) 71-83.
Arrowsmith et al., “Long-Acting Dihydropyridine Calcium Antagonists. 1. 2-Alkoxymethyl Derivatives Incorporating Basic Substituents”, J. Med. Chem. American Chemical Society, 1986, 29, 1696-1702.
FDA FOIA Material on Amlodipine Besylate, NDA No. 19-787, “Review of an Original NDA”, Oct. 10, 1990.
Benneker Franciscus B. G.
Lemmens Jacobus M.
Peters Theodorus H. A.
Fleshner & Kim LLP
Krass Frederick
Synthon BV
LandOfFree
Aspartate derivative of amlodipine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aspartate derivative of amlodipine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aspartate derivative of amlodipine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2953789